Remarkable response of a patient with secondary glioblastoma to a histone deacetylase inhibitor
Keyword(s):
Abstract Secondary glioblastoma is a rare brain tumor characterized by a mutation in isocitrate dehydrogenase, which is reported to lead to epigenetic modification. Patients with secondary glioblastoma experience poor survival and quality-of-life outcomes due to the disease’s aggressiveness and a lack of targeted therapies. In this report, a patient with a secondary glioblastoma was treated with a histone deacetylase inhibitor, an epigenetic drug with potent anti-inflammatory properties, in addition to the standard regimen. The patient showed very favorable survival and quality-of-life measures, and a restoration of several neuro-metabolites as measured by spectroscopic magnetic resonance imaging.
2017 ◽
Vol 35
(6)
◽
pp. 691-705
◽
2007 ◽
Vol 2007
◽
pp. 53
2015 ◽
Vol 9
(3)
◽
pp. 125-134A
◽
2011 ◽
Vol 2
(2)
◽
pp. 127-135
◽